- $210.02m
- $180.17m
- $4.06m
Annual income statement for Ocugen, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.043 | 0 | 2.49 | 6.04 | 4.05 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 21.3 | 57.6 | 91.6 | 71.6 | 58.8 |
| Operating Profit | -21.3 | -57.6 | -89.1 | -65.5 | -54.8 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -21.8 | -58.4 | -86.8 | -63.1 | -54.1 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -21.8 | -58.4 | -86.8 | -63.1 | -54.1 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -21.8 | -58.4 | -86.8 | -63.1 | -54.1 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -34.4 | -58.4 | -86.8 | -63.1 | -54.1 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.306 | -0.301 | -0.404 | -0.258 | -0.199 |